Cavadex® | Innovating Heart Health
At Cavadex®, we are dedicated to transforming cardiovascular care with cutting-edge science. Our proprietary compound, 2-hydroxypropyl-β-cyclodextrin, is the only cyclodextrin proven to safely reduce arterial plaque and improve heart health. Backed by over 30 years of FDA approved cyclodextrin research, Cavadex® offers a groundbreaking solution for managing atherosclerosis and supporting overall cardiovascular wellness.
We work closely with leading cardiologists, researchers, and healthcare professionals to deliver a product that redefines how cardiovascular disease is treated. Our commitment to innovation, safety, and patient outcomes drives us to make this life-changing therapy accessible to individuals globally.
What We Offer:
• Scientifically proven treatment for reducing arterial plaque
• Support for cholesterol management and cardiovascular health
• Global distribution and customer support
Join us in our mission to make heart health more achievable, one patient at a time.
Learn more at: www.cavadex.com
Follow us for updates on cardiovascular innovation and patient success stories.
Company Details
- Founded
- -
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- http://www.cholrem-cavadex.com
Cavadex Questions
Cavadex's website is http://www.cholrem-cavadex.com
Cavadex's LinkedIn profile is https://www.linkedin.com/company/cavadex
Cavadex's industry is
Research Services
Cavadex's top competitors are
Comac Retail Property Group,
Loan Market Vantage,
Gutsy Media,
Tinker Labs International,
Aurora Information Technology,
Titan Prehospital Innovation,
Atherocare,
Imagency,
Evolved Recruitment Solutions,
Neuronetix.
Cavadex's categories are Research Services
Cavadex's founding year is 2019
